Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial
- Conditions
- Pre-terminal Cancer
- Interventions
- Drug: Heart failure medicationDrug: Placebo
- Registration Number
- NCT05636774
- Lead Sponsor
- University Hospital, Essen
- Brief Summary
The pathophysiological implications of various cancer diseases and anti-cancer therapies is the occurrence of a cardiac disease-like phenotype with cardiac dysfunction, cardiac wasting, and cardiac homeostasis changes (incl. fibrosis and apoptosis) in end-stage cancer patients, causing heart failure like syndrome with development of congestion, dyspnoea and severely reduced physical functioning. The present trial aims to evaluate, if a heart failure medication improves the self-care ability and self-reported health care status of patients with pre-terminal cancer in palliative care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 72
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Heart failure medication arm Heart failure medication Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin Placebo arm Placebo Placebo tables / infusion
- Primary Outcome Measures
Name Time Method Days alive and able to wash themselves since baseline during 30 days of follow-up patient performed act of washing by him/her-selves without interference of staff (regardless of whether as shower or bath, on a sink, or using a "sponge bath" in the bed)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Essen
🇩🇪Essen, NRW, Germany